The lab said Monday that it will offer the prices in the developed countries of the world, to create a model for the same price.
(Boursier.com) — The laboratory Gilead Sciences announced on Monday that it would charge 390 dollars the u.s. government and other developed countries for a vial of his Remdesivir, a drug against the coronavirus, which is approximately 2.340 dollars for a typical treatment of 5 days. Gilead has said that it will offer the prices in the developed countries around the world in order to create a model for the same price, which would avoid the need to negotiate rates on a country by country, hindering access to treatment…
The price will “that all patients around the world have access to this drug,” said general director Daniel O’day said in an interview.
The price of 390 dollars per bottle will be in a first-time direct sales to governments and after that the offer will be less tense, Gilead will begin selling the drug in normal channels to 520 dollars the bottle, or 3.120 dollars for five days.
Authorization in the United States
The Remdesivir is one of the first drugs widely used to fight against the Covid-19. It has received an authorization of emergency use of the United States. Hundreds of treatments and vaccines are under development around the world and thousands of researchers are mobilized to try to fight a global pandemic which has infected more than 10 million people and killed more than 500,000.
The price of the Remdesivir has been the subject of intense debate since the Food and Drug Administration of the United States (drug agency) has approved its emergency use in some patients in may. Experts said that Gilead should not enjoy the benefits of a health crisis…
Billions of profits ?
According to analysts of Wall Street, the anti-retroviral drug could generate billions of dollars of revenue over the next two yearsif the pandemic continues… Gilead has partnered with manufacturers of generic drugs based in India and Pakistan, including Cipla and Hetero Labs to manufacture and provide the Remdesivir in 127 developing countries.
The action Gilead has made progress in the scholarship of 15% since the beginning of the year…